Townsend John 4/A

What Happened John Townsend, Chief Financial Officer of Unicycive Therapeutics (UNCY), received a grant of 169,500 restricted stock units (RSUs) reported as a derivative award on May 14, 2026. The RSUs were granted at $0.00 (no cash paid). The filing was amended and submitted on June 15, 2026.

Key Details

• Transaction type: Award / Grant (code A) — 169,500 RSUs at $0.00 (derivative).
• Transaction date: 2026-05-14; amended Form 4 filed: 2026-06-15 (late/amended filing).
• Vesting footnote: the RSU award footnote states 23,542 shares vest upon grant and 4,708 shares vest over 31 months beginning June 1, 2026 (total stated in footnote = 28,250 vested per that schedule). The Form 4 reports a larger gross grant (169,500 RSUs); the filing does not clarify the breakdown for the remainder.
• Shares owned after transaction: Not specified in this Form 4.
• No tax withholding, sale, or 10b5-1 plan is disclosed in this filing.

Context RSUs are a common form of executive compensation and are payable in company common stock upon vesting; they do not require cash purchase by the insider and do not indicate an immediate market transaction (no shares sold or bought). Because this is an amended, late-filed Form 4, investors should review future filings for clarifying detail on the full vesting schedule or any corrections.